For anyone who takes the time to discern the actual outcomes of currently available Alzheimer’s treatment drugs, this promotion of “more is better” is, on the face of it, laughable.
Unless one understands that current Alzheimer’s treatments are very ineffective, that they, at best, provide for slightly increased cognitive function for short initial periods (weeks or months), the announcement sounds good and reasonable.
The drugs are rather expensive, have lots of adverse events (“side effects”), don’t provide really useful cognitive restoration, and after the initial period of slightly-improved thinking, AD patients continue on their tragic mental decline, as though never having had the drug.
The only useful new treatment will be Anavex 2-73; of which there was no mention. Nor will there be, even after Wednesday’s favorable efficacy data are released. As I’ve posted before, the entire medical treatment and research community is certain that Alzheimer’s is directly caused by a-beta deposits and tau-tangles, and they’ve learned that several previous drugs aimed at clearing these waste neuron proteins have been utterly ineffective, with severe side effects. With that thinking, the only alternative is the called-for increase in the rather short-lived, ineffective acetylcholinesterase inhibitor drugs.
It took 19th-century physicians many decades to come to the realization that infectious diseases are caused by microbes, germs. Physicians are extremely resistant to any concepts or ideas not taught to them in med school.
The FDA approval and prescribed use of Anavex 2-73 is going to be a threat to conventional medicine for several reasons. First, it simply contradicts what is “clearly known” about Alzheimer’s (as mentioned above). Far worse (from the physicians’ personal viewpoint), will be the drug’s threat to medical practice services and fees. The treatment of Alzheimer’s and other neurodegenerative diseases (most of which will be markedly reduced by 2-73) will threaten the multi-billion dollar dementia and neurodegenerative medical sector. Instead of expensive, closely-monitored drugs and personal care requirements for contemporary Alzheimer’s patients, general practitioners (or nurse practitioners) will simply prescribe a daily dose of, say, 30mgs of 2-73, thereby terminating, even reversing the progression of the earliest Alzheimer’s symptoms. The only applicable medical term will then be, “Next patient, please.” Simple office visit stuff.
News 
Market Data 
Discover 
